PSK Pharma received a registration certificate for Etravirine PSK and brought it to the Russian market, the second in the company’s line of therapies for human immunodeficiency virus. This was reported in the company’s press service.
The drug is available in tablets containing 200 mg of the active substance with the same name. Etravirin PSK is intended for the treatment of HIV-1 in adults and children from two years of age with a body weight of more than 30 kg who previously received antiretroviral therapy.
“Etravirin PSK is a non-nucleoside reverse transcriptase inhibitor. It is an antiretroviral drug that helps achieve zero viral load by affecting reverse transcriptase (enzyme) in an HIV-positive patient. This enzyme is necessary to ensure the viability of retroviruses, including those of the HIV group. The drug blocks it, and due to this, viral RNA and DNA responsible for the reproduction of infections are not synthesized. Thus, the active substance of the drug stops the spread of the virus, significantly improving the patient’s quality of life and life expectancy. To achieve the maximum therapeutic effect, doctors prescribe Etravirine in combination with other HIV drugs,” the report says.
In 2020, PSK Pharma registered another antiretroviral drug, Fosamprenavir PSK. In addition to the registered dosage of 200 mg of Etravirine PSK, the company is developing additional children’s dosages with a lower concentration of the active substance necessary for the treatment of HIV infection in patients under two years of age or with a body weight of less than 30 kg.